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Abstract
The human coronaviruses (HCoVs) are an important etiology of community-acquired respira-
tory tract infections. Community-acquired pneumonia (CAP) may be caused by serotypes of 
endemic HCoVs or highly pathogenic HCoVs. In this review we compared the clinical charac-
teristic, management, outcomes, and infection control practices for patients with CAP due to 
endemic HCoVs versus patients with CAP due to 2019 novel coronavirus (SARS-CoV-2).
Introduction
There are four serotypes of HCoVs that are endemic and three highly pathogenic HCoVs 
(Figure 1). Endemic HCoVs cause respiratory tract infection in children and adults glob-
ally. We recently reported our experience with adults hospitalized with CAP due to en-
demic HCoVs in the city of Louisville, Kentucky.[1] The first cases of CAP due to highly 
pathogenic HCoVs, the severe acute respiratory syndrome coronavirus (SARS-CoV), 
were identified in China in 2002.[2] Cases of CAP due to a second highly pathogenic 
HCoV, the Middle East respiratory syndrome coronavirus (MERS-CoV), were identified 
in Saudi Arabia and Qatar in 2012.[3,4] More recently, cases of CAP due to the 2019 novel 
coronavirus (2019-nCoV) were identified in the city of Wuhan, China at the end of 2019.
[5] Based on phylogeny, this new coronavirus is recognized as a sister of the SARS-CoV, 
and the Coronavirus Study Group of the International Committee on Taxonomy of Vi-
ruses is proposing to designate this new virus as severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2).[6] The World Health Organization is now officially calling the 
disease COVID-19 (CO for corona, VI for virus, D for disease, and 19 for the year 2019). 
Having a name for the virus (2019-nCoV or SARS-CoV-2) and a different name for the 
disease (COVID-19) will help with the nomenclature of future coronavirus outbreaks. 
The spectrum of disease for patients presenting with COVID-19 is depicted in Figure 2. 
In this manuscript we first compared the clinical characteristics and outcomes of pa-
tients with CAP due to endemic HCoVs admitted to hospitals in the city of Louisville [1] 
versus patients with CAP due to the 2019-nCoV admitted to hospitals in the city of Wu-
han.[7] We subsequently reviewed our current understanding of the risk factors, diagno-
sis, infection control practices, and management of patients with CAP due to endemic 
HCoVs and the 2019-nCoV or SARS-CoV-2. 
Clinical Presentation and Outcomes
The demographics, comorbidities, and signs and symptoms of 42 patients hospitalized 
with endemic HCoVs as the only etiology of CAP from the city of Louisville [1] and the 
first 41 patients reported in the literature with CAP due to the 2019-nCoV from the city 
of Wuhan [7] are depicted in Table 1. The age distribution of both groups is depicted in 
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Figure 1. Serotypes of HCoVs globally endemic and highly pathogenic. SARS-CoV: Severe 
acute respiratory syndrome coronavirus. MERS-CoV: Middle East respiratory syndrome 
coronavirus. 2019-nCoV: 2019 novel coronavirus or SARS-CoV-2: Severe acute respiratory 
syndrome coronavirus 2.
Figure 3. Patients infected with the 2019-nCoVs are younger and present with less comorbidities when compared to 
patients infected with endemic HCoVs. Table 2 compares the laboratory and radiographic findings of both groups. 
Patients with CAP due to 2019-nCoV presented with lower white blood cells count and higher elevations in liver en-
zymes. In both groups of patients, procalcitonin levels were low, as expected of patients with viral CAP. The presence 
of pulmonary infiltrates with bilateral involvement was present in almost 100% of patients in both groups.  The treat-
ments and outcomes of both groups are depicted in Table 3. In the initial report of CAP due to 2019-nCoV, the high 
mortality of 15% was likely a reflection of a more critically ill population of patients being initially recognized with the 
disease. A second case series, including 139 hospitalized patients with 2019-nCoV, reported a mortality of 4%.[8] This 
mortality is similar to the one that we reported for hospitalized patients with endemic HCoVs of 2%.  
Risk Factors and Diagnosis
The incubation period of 2019-nCoV is thought to range from 3 to 14 days, with most patients developing clinical man-
ifestations within the first week following exposure. Since an infected  person may be asymptomatic for up to 14 days, a 
patient with fever and/or symptoms of respiratory tract infection should be considered at risk of 2019-nCoV infection 
if: 1) the patient, within the prior 14 days, resided in or traveled to China, or 2) the patient, within the prior 14 days, had 
close contact with a confirmed or suspected case of 2019-nCoV infection. In a patient at risk of 2019 nCoV infection, 
the diagnosis is confirmed by performing a PCR of specimens from the upper respiratory tract (e.g. nasopharyngeal or 
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oropharyngeal secretions) using 2019-nCoV primers. 
Infection Control Measures
There are four areas of infection control practice that are relevant for the safety of healthcare workers caring for pa-
tients with CAP due to endemic HCoVs as well as the 2019-nCoV. They include early recognition and isolation, selec-
tion and use of personal protective equipment, performance of hand hygiene, and environmental infection control. The 
specific infection control recommendations for endemic HCoVs and 2019-nCoV are depicted in Table 4.
Table 1. Demographics, comorbidities, and signs and symptoms of 42 patients 
with CAP due to endemic CoVs from the city of Louisville and the first 41 
patients reported in the literature with CAP due to the 2019-nCoV from the city 
of Wuhan.
Variable Louisville Endemic CoV
Wuhan
2019-nCoV
Total N 42 41
Demographics
Age, years 71 [54,82] 49 [41, 58]
Sex (%)
Men 18 (43) 30 (73)
Women 24  (57) 11 (27)
Current Smoker (%) 9 (21) 3 (7)
Comorbidities
Any Comorbidity (%) 39 (93) 13 (32)
Diabetes (%) 15 (36) 8 (20)
Hypertension (%) 30 (71) 6 (15)
Cardiovascular disease (%) 15 (36) 6 (15)
Chronic obstructive pulmonary disease (%) 15 (36) 1 (2)
Malignancy or active neoplastic disease (%) 7 (17) 1 (2)
Liver Disease (%) 3 (7) 1 (2)
Signs and symptoms
Highest temperature, °C (%)
<37.3 20 (48) 1 (2)
37.3-38.0 4 (10) 8 (20)
38.1-39.0 11 (26) 18 (44)
>39.0 7 (17) 14 (34)
Systolic pressure, mm Hg 120 [103.0 - 133] 125 [119.0 - 135.0]
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Figure 3. Age distribution of 42 patients with CAP due to endemic human CoVs from the city of 
Louisville and the first 41 patients reported in the literature with CAP due to the 2019-nCoV or 
SARS-Cov-2 from the city of Wuhan.
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In a recent report of 138 patients hospitalized with 2019-nCoV infection, the authors estimated that nosocomial trans-
mission of the virus may have occurred in 40% of the patients.[8] They considered transmission from patient to patient 
in 17 patients (12%) and transmission from patient to health care worker in 40 patients (29%). It is important that sev-
eral patients in this report were not placed in respiratory isolation at the time of hospital admission because the initial 
patient’s complaints were related to atypical abdominal symptoms. As depicted in Figure 2, some patients may have 
a gastrointestinal syndrome as initial presentation of Covid-19. In these cases, the virus may be transmitted via the fe-
cal-oral route. 
ICU Management
Some parallels can be made to the prior two epidemic strains, MERS-CoV and SARS-CoV in transmission and clinical 
features and thus ICU management strategies implemented in those epidemics could be applied currently. Clinicians at 
University of Toronto described specific challenges in oxygenating patients with SARS-CoV.[9] The use of oxygen ther-
apy with aerosol humidifiers was suspected to increase the risk of droplet transmission. Additional routine ICU proce-
Table 2. Laboratory and radiographic findings of 42 patients with CAP 
due to endemic CoVs from the city of Louisville and the first 41 patients 
reported in the literature with CAP due to the 2019-nCoV from the city of 
Wuhan.
Variable Louisville Endemic CoV
Wuhan 
2019-nCoV
Total N 42 41
Laboratory and Radiological Findings
White blood count per 1000/microL 11.0 [9.1 - 15.2] 6.2 [4.1 - 10.5]
<4 2/41 (5) 10/40 (25)
4-10 14/41 (34) 18/40 (45)
>10 25/41 (61) 12/40 (30)
Platelets per 1000/microL (%) 229 [173 - 266] 164.5 [131.5 - 263.0]
<100 2/42 (5) 2/40 (5)
≥100 40/42 (95) 38/40 (95)
Albumin, g/dL 36.0 [34.0 - 40.0] 31.4 [28.9 - 36.0]
Alanine transferase (ALT) (units/L) 27 [21 - 36] 32 [21 - 50]
Aspartate transaminase (AST) (units/L) 23 [20 -32] 34 [26 - 48]
≤40 32/39 (82) 26/41 (63)
>40 7/39 (18) 15/41 (37)
Bilirubin (mg/dL) 0.6 [0.5 - 0.9] 0.7 [0.6 - 0.8]
Potassium (mmol/L) 4.0 [3.7 - 4.4] 4.2 [3.8 - 4.8]
Serum sodium (mmol/L) 138 [135 - 140] 139 [137 - 140]
Procalcitonin (microg/mL) 0.1 [0.1 - 0.3] 0.1 [0.1 - 0.1]
<0.1 7/14 (50) 27/39 (69)
≥0.1 to <0.25 3/14 (21) 7/39 (18)
≥0.25 to <0.5 2/14 (2) 2/39 (5)
≥0.5 2/14 (2) 3/39 (8)
Hypersensitive troponin (pg/mL) 20.5 [10.0 - 38.5] 3.4 [1.1 - 9.1]
>28 12/28 (43) 5/41 (12)
Bilateral involvement of chest radiographs 41/42 (98) 40/41 (98)
Table 3. Treatment and outcomes of 42 patients with CAP due to 
endemic CoVs from the city of Louisville and the first 41 patients reported 
in the literature with CAP due to the 2019-nCoV from the city of Wuhan.
Variable Louisville Endemic CoV
Wuhan 
2019-nCoV
Total N 42 41
Treatments and Clinical Outcomes
Shock with need for vasopressors (%) 3 (7) 3 (7)
Non-invasive ventilation (%) 3 (7) 10 (24)
Invasive mechanical ventilation (%) 3 (7) 2 (5)
Death (%) 1 (2) 6 (15)
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dures were deemed high risk due to infection control concerns including intubation and extubation, nasopharyngeal 
swab, bag-valve-mask ventilation, suctioning, non-invasive positive pressure ventilation (NIPPV), and high frequency 
oscillation. Disconnection from the ventilator and manual bag ventilation was discouraged due to concerns for droplet 
spread even in cases of cardiac arrest unless an obvious mechanical failure was suspected. 
Ventilator management of SARS-CoV mirrored that of acute respiratory distress syndrome (ARDS). Similar observa-
tions were made with the MERS-CoV outbreak as described by clinicians in Jeddah, Saudi Arabia.[10] Management of 
respiratory failure with NIPPV was strongly discouraged as it almost always lead to intubation and also carried signif-
icant risk of droplet spread. 
In patients who develop ARDS leading to invasive ventilation, we consider a strategy of low tidal volume (4 to 6 ml/
Kg of predicted body weight) and the use of positive-end-expiratory pressure titrated according to the requirement of 
oxygen. The plateau pressure should be maintained at less than 30 cmH2O.[11] We also consider monitoring driving 
pressure, since higher driving pressure values have been associated with higher mortality in patients with ARDS.[12] 
In the setting of refractory hypoxia, other strategies should be considered such as prone position and extracorporeal 
membrane oxygenation.[13,14]
Therapy
The majority of the proposed therapies for CAP due to human coronavirus came to light during the SARS-CoV and 
MERS-CoV outbreaks in 2003 and 2012, respectively. Treatment options evaluated in clinical studies included antivi-
rals, such as ribavirin, antiretrovirals such as lopinavir/ritonavir, steroids, interferon, and macrolides. In most reports, 
these therapies have been used in combination without a clear clinical benefit. 
Remdesivir is a novel nucleotide analogue with activity against SARS and MERS-CoV in vitro and in animal studies.[15] 
Remdesivir was utilized as a compassionate use investigational drug in the first described US case of 2019-nCoV in Jan-
uary 2020.  The patient had mild initial symptoms that progressed to pneumonia on the ninth day of admission, with 
rapid clinical improvement after treatment with remdesivir. This novel agent is being considered for further random-
ized clinical trials in China to establish efficacy in humans during the current 2019-nCoV outbreak. Investigators from 
the National Institute of Allergy and Infectious Diseases (NIAID) are preparing to test remdesivir, as well as lopinavir/
ritonavir (Kaletra), and interferon-beta for their activity against 2019-nCoV.[16]
Prospect for a Vaccine
The NIAID Vaccine Research Center is leading the efforts to develop a vaccine for the 2019-nCoV. Investigators are 
using a messenger RNA platform to produce the viral spike protein of 2019-nCoV. The NIAID anticipates the experi-
mental vaccine will be ready for testing in a phase 1 trial in the coming months.[16]
Endemic HCoVs 2019-nCoV or SARS-CoV-2 
Isolation: Standard precautions, private 
room not required
Personal Protective Equipment: Not 
recommended
Hand Hygiene: Alcohol-based hand rubs
Environmental Disinfection: Use of an EPA-
registered disinfectant approved for use in 
healthcare. 
Isolation: Airborne isolation room providing 
verified negative airflow in combination with 
contact isolation
Personal Protective Equipment: Barrier use 
(e.g., eye protection, gowns and gloves) to 
prevent contact with body fluids, such as 
respiratory secretions that may be projected 
during cough. Respirator use in accordance 
with airborne isolation.  
Hand Hygiene: After removal of gloves, 
alcohol-based hand rubs
Environmental Disinfection: Use of an EPA-
registered disinfectant approved for use in 
healthcare. 
Table 4. Specific infection control recommendations for patients infected with endemic human 
coronaviruses (HCoVs) and 2019 novel coronavirus (2019-nCoV) or Severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2).
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Conclusions
Patients with CAP due to 2019-nCoV tend to be younger, and with less comorbidities than patients with CAP infected 
with endemic HCoVs, however, the clinical presentation and outcomes for both groups of patients is similar. Optimal 
implementation of infection control practices is important to contain the 2019-nCoV spread in the community and 
hospital setting. Patients hospitalized with CAP due to 2019-nCoV have a mortality of approximately 3%, very similar 
to the mortality of hospitalized patients with CAP due to endemic HCoVs. Mortality of hospitalized patients with CAP 
due to 2019-nCoV is expected to decrease as new therapeutic strategies are developed. 
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